Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid

Affiliations

¹ Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.

Comment

Paul D Miller et al. J Clin Endocrinol Metab. 2016 Sep.

. 2016 Sep;101(9):L91-2.

doi: 10.1210/jc.2016-2902.

¹ Colorado Center for Bone Research (P.D.M.), Lakewood, Colorado; Amgen Inc. (N.P., R.B.W.), Thousand Oaks, California; and San Francisco Coordinating Center (S.R.C.), CPMC Research Institute, San Francisco, California.

No abstract available

Comment on

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR. Miller PD, et al. J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70. doi: 10.1210/jc.2016-1801. Epub 2016 Jun 6. J Clin Endocrinol Metab. 2016. PMID: 27270237 Free PMC article. Clinical Trial.
Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
Makras P, Polyzos SA, Anastasilakis AD. Makras P, et al. J Clin Endocrinol Metab. 2016 Sep;101(9):L89-90. doi: 10.1210/jc.2016-2457. J Clin Endocrinol Metab. 2016. PMID: 27600205 No abstract available.